Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib in Newly Diagnosed Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)
NCT00850382Phase 2Completed
- Sponsor
- Ulm University
- Start
- Jun 2009
- Primary completion
- Nov 2015
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of dasatinib in acute myeloid leukemia (AML), sponsored by Ulm University. Primary endpoint: Feasibility (Rate of ED/HD, pleural/pericardial effusion, liver toxicity, refractory disease) at 4 weeks. Started Jun 2009; status: completed.
02
Drugs
dasatinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00850382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00850382.